Biogen (BIIB.US) and UCB's new lupus drug, Dupixent, succeeds in late-stage trials, reversing early failure shadow
Tuesday, Sep 24, 2024 4:20 am ET
1min read Biogen (BIIB.US) and its Belgian partner UCB on Tuesday announced that their experimental lupus treatment, dupilumab, met its primary goal in late-stage trials, a surprising reversal after the drug failed in early mid-stage studies. If the success is confirmed in a second late-stage study, it could provide new treatment options for lupus patients, especially in an area where trials have failed and approved therapies are limited. The companies plan to start the second study later this year.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.